Dr. Heloisa Prado Soares, MD

Dr. Soares practices at University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah.

Dr. Soares' NPI, 1033435490, was assigned on April 10, 2010. Dr. Soares holds Utah license 11410986-1205.

Dr. Soares' primary practice is University of Utah Hospitals and Clinics - Unit, at 50 North Medical Drive, Salt Lake City, UT 84132 in Salt Lake County. The practice phone is (801) 581-2337.

Dr. Soares' primary practice is University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah. Dr. Soares is also affiliated with University of Utah Hospital. The medical group on file is University of Utah Health. Dmand AI also links Dr. Soares to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Soares practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Soares' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Soares' licenses on file in 4 states: Utah, California, Florida and New Mexico.

CMS data shows 607 Medicare services from Dr. Soares across 7 procedure codes in 2024, for 144 Medicare patients. Medicare paid $36,708 for them.

CMS counts 144 Medicare patients who saw Dr. Soares in 2024. The largest group is 65 to 74, with 77 patients. 70% of them have high blood pressure, and 56% have high cholesterol. 8% are also on Medicaid. Their average risk score is 2.78, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Soares' median patient age at 71, with 53% women.

In 2024, Dr. Soares wrote 208 Medicare Part D claims for 61 patients. 76% of them were for generic drugs. CMS names the drug for 62 of them, across 4 drugs with 11 or more claims each, at $51,984 in total drug cost. In 2023, CMS named 99 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Soares for performance year 2024, reported as part of a group. Dr. Soares accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Soares as offering telehealth.

Dmand AI links 46 papers to Dr. Soares, published from 2012 to 2025. 2023 was the busiest year, with 6. The most frequent topics are Pancreatic Neoplasms, Neuroendocrine Tumors and Carcinoma, Pancreatic Ductal. Dr. Soares has published most often in Cancers (Basel). Dr. Soares' most frequent co-authors are Jonathan R. Strosberg, MD, Aman Chauhan, MD and Emil Lou, MD, PhD.

Dmand AI links Dr. Soares to 11 clinical trials, 5 of them phase 3 studies. 8 are still active or recruiting. Conditions studied include Rectal Diseases, Colorectal Neoplasms and Anal Canal Carcinoma. National Cancer Institute (NCI) sponsors the most, 7. Open Payments lists research payments to Dr. Soares that name 1 trial.

CMS Open Payments shows 199 general payments to Dr. Soares from 27 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 54% of the total. Exelixis Inc. paid the most, $27,500. It also lists 6 research payments totaling $13,678 from 2016 to 2025, naming 1 clinical trial.